Myeloma Institute for Research and Therapy
Home
What is Myeloma?
About the Institute
Referring or
Becoming a Patient
Our Doctors and Staff
  Our Doctor Team
  Our Nursing Team and Other Health Professionals
UAMS
News/Events/Press Releases
Scientific Publications/Research
About Little Rock & Arkansas
About UAMS
About The Winthrop P. Rockefeller Cancer Institute
Travel, Hotels, Directions & Maps, UAMS Dining
Other Sources of Myeloma Information
Contact Us
Make a Donation

Job Opportunities

Research Faculty

YaccobyPhDShmuel.jpg (8262 bytes)Shmuel Yaccoby, Ph.D.
Associate Professor of Medicine and Physiology

Ph.D., Department of Animal Science, The Hebrew University of Jerusalem, Israel
Post –doctoral study at the Department of Physiology-Biophysics, University of Arkansas for Medical Sciences
Research Fellow, Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences
Research interest: Dr. Yaccoby seeks to elucidate the roles of various cells in the bone marrow microenvironment, such as bone and neovascular endothelial cells, in the pathogenesis of multiple myeloma. He is also studying the interaction between human hematopoietic stem cells and bone cells.

Selected Publications:

Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy, JD Jr: Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple growth in-vivo. Blood 109:2106-11, 2007.

Yaccoby S, Johnson CL, Mahaffey S, Wezeman MJ, Barlogie B, Epstein J: Anti-myeloma efficacy of thalidomide in the SCID-hu model. Blood 100: 4162-4168, 2002

Yaccoby S, Wezeman MJ, Henderson A, Fox MH, Qing Y, Barlogie B, Epstein J: Cancer and the microenvironment: Myeloma-osteoclast interactions as a model. Cancer Res. 64: 2016-2023, 2004.

Yata K, Yaccoby S: The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia 18: 1891-1897, 2004.

Yaccoby S: The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, apoptosis-resistant phenotype. Clinical Cancer Research. 11: 7599-7606, 2005. 

Yaccoby S, Wezeman MJ, Zangari M, Walker R, Cottler-Fox M, Gaddy D, Ling W, Saha R, Barlogie B, Tricot G, Epstein J: Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica. 91: 192-199, 2006.

Ge Y, Zhan F, Barlogie B, Epstein B, Shaughnessy J, Yaccoby S: Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival. Br J Haematol. 133: 83-92, 2006.

 

 

About Multiple Myeloma // About the Myeloma Institute // Becoming a Patient
Highlights of Our Myeloma Program  // Our Physician Team // Our Nursing Team
News/Events/Press Releases // Scientific Publications/Research
About Little Rock & Arkansas // About UAMS // About The Winthrop P. Rockefeller Cancer Institute
Travel/Directions/Maps // Contact Us // Make a Donation

Having problems with the site? E-mail the Webmaster.
Copyright 2002-2005, Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
Terms and Conditions of Use

The information on the Myeloma Institute web site is not intended as a substitute for professional medical attention. The information is intended only as an aid in understanding current medical knowledge. A physician should always be consulted for any health concern or medical condition. The Myeloma Institute web site provides links to other organizations as a service to our readers. The Myeloma Institute is not responsible for the information provided on other web sites.

Notice of Privacy Practices
Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences